Tag: Bayer
Finerenone to be trialled for CKD in type 1 diabetes patients
Bayer has announced the initiation of FINE-ONE, a global, multicentre, randomised, placebo-controlled, double-blind, parallel-group Phase III study to evaluate the efficacy and safety of...
NHS Scotland treatment of CKD with finerenone accepted by SMC
Bayer has announced that Kerendia (finerenone, 10mg and 20mg), an oral, first-in-class non-steroidal, selective mineralocorticoid receptor (MR) antagonist, has been accepted for use within...